| 196.165 0.915 (0.47%) | 11-14 13:11 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 229.17 |
1-year : | 267.67 |
| Resists | First : | 196.21 |
Second : | 229.17 |
| Pivot price | 189.49 |
|||
| Supports | First : | 189.07 |
Second : | 184.66 |
| MAs | MA(5) : | 193.61 |
MA(20) : | 190.19 |
| MA(100) : | 176.93 |
MA(250) : | 163.14 |
|
| MACD | MACD : | 1.9 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 94.1 |
D(3) : | 87.9 |
| RSI | RSI(14): 69.6 |
|||
| 52-week | High : | 196.21 | Low : | 140.67 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ JNJ ] has closed below upper band by 2.1%. Bollinger Bands are 26.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 196.02 - 196.7 | 196.7 - 197.33 |
| Low: | 191.46 - 192.35 | 192.35 - 193.17 |
| Close: | 193.84 - 195.08 | 195.08 - 196.21 |
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Fri, 14 Nov 2025
Bears CB Jaylon Johnson returns to practice Friday - Chicago Sun-Times
Fri, 14 Nov 2025
Woody Johnson Is Sick Of Everyone Knowing What A Lousy Workplace He Oversees - Defector
Fri, 14 Nov 2025
Man who grabbed Ariana Grande on ‘Wicked: For Good’ red carpet charged - New York Post
Fri, 14 Nov 2025
Who Attacked Ariana Grande at the ‘Wicked’ Premiere? Johnson Wen’s Identity Revealed and Arrest Update - Cosmopolitan
Fri, 14 Nov 2025
Risers and fallers: Jalen Johnson on his way to superstar status - ESPN
Thu, 13 Nov 2025
4-star PG Marcus Johnson, former Ohio State pledge, commits to South Carolina - On3
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,410 (M) |
| Shares Float | 2,400 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 74.3 (%) |
| Shares Short | 20,630 (K) |
| Shares Short P.Month | 22,050 (K) |
| EPS | 10.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 32.95 |
| Profit Margin | 27.2 % |
| Operating Margin | 30.2 % |
| Return on Assets (ttm) | 8.2 % |
| Return on Equity (ttm) | 33.6 % |
| Qtrly Rev. Growth | 6.8 % |
| Gross Profit (p.s.) | 26.13 |
| Sales Per Share | 38.23 |
| EBITDA (p.s.) | 13.24 |
| Qtrly Earnings Growth | 91 % |
| Operating Cash Flow | 24,200 (M) |
| Levered Free Cash Flow | 12,010 (M) |
| PE Ratio | 18.93 |
| PEG Ratio | 0 |
| Price to Book value | 5.95 |
| Price to Sales | 5.13 |
| Price to Cash Flow | 19.53 |
| Dividend | 1.29 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|